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High frequencies of antimicrobial drug resistance were 
observed in O157 and non-O157 Shiga toxin–producing 
E. coli strains recovered from patients in Michigan during 
2010–2014. Resistance was more common in non-O157 
strains and independently associated with hospitalization, 
indicating that resistance could contribute to more severe 
disease outcomes.
Shiga toxin–producing Escherichia coli (STEC) con-tributes to 265,000 cases of foodborne illness annually 
in the United States (1). Most infections are caused by 
O157 strains; however, non-O157 STEC infections have 
increased (2). Antimicrobial drug resistance among STEC 
has been reported (3–5) but is probably underestimated. 
Given the importance of resistance in E. coli pathotypes, 
we sought to determine the prevalence of resistant STEC 
infections and assess the effects of resistance on disease.
We obtained 358 STEC isolates from the Michigan 
Department of Health and Human Services (MDHHS) Ref-
erence Laboratory (Lansing, MI, USA), collected during 
2010–2014. Of these, 14 were outbreak associated. We ex-
amined 1 strain per outbreak using protocols approved by 
Michigan State University (MSU; Lansing, MI, USA; IRB 
#10-736SM) and MDHHS (842-PHALAB). Overall, 31 
(8.8%) strains (23 non-O157, 8 O157) were resistant to anti-
microbial drugs (Table). Resistance to ampicillin (7.4%) was 
most common, followed by trimethoprim/sulfamethoxazole 
(SXT) (4.0%) and ciprofloxacin (0.3%). Compared with 
national rates, resistance to ampicillin and SXT was higher, 
but not significantly different, for O157 isolates from Michi-
gan (online Technical Appendix Figure 1, https://wwwnc.
cdc.gov/EID/article/23/9/17-0523-Techapp1.pdf) (6). One 
strain was resistant to all drugs, and all resistant strains had 
high MICs (ampicillin, >64 μg/mL; ciprofloxacin, >32 μg/
mL; SXT, in 1:19 ratio, >32/608 μg/mL). Notably, resistance 
was twice as common for non-O157 (11.1%) than for O157 
(5.5%) strains. O111 strains (n = 7) had significantly higher 
resistance frequencies (24.1%) than other non-O157 sero-
groups (p = 0.03). We found variation by year and season; re-
sistance frequencies were highest in 2012 (online Technical 
Appendix, Figure 2) and during winter/spring (online Tech-
nical Appendix Table 1), but neither trend was significant. 
We also observed a strong but nonsignificant association be-
tween resistance and hospitalization but no association for 
urban versus rural residence (7) or county after stratifying by 
prescription rates (8) in the univariate analyses.
We conducted a multivariate analysis using logistic 
regression, with hospitalization as the dependent vari-
able; we included variables with significant (p<0.05) and 
strong (p<0.20) associations from the univariate analysis 
as independent variables. Forward selection indicated that 
hospitalized patients were more likely to have resistant 
infections (odds ratio [OR] 2.4, 95% CI 1.00–5.82) and 
less likely to have non-O157 infections (OR 0.4, 95% CI 
0.21–0.61) (online Technical Appendix Table 2), suggest-
ing that resistant infections or O157 infections may cause 
more severe clinical outcomes. Patients >18 years of age, 
women, and patients with bloody diarrhea were also more 
likely to be hospitalized. 
Although we found no significant difference by stx 
profile, strains possessing stx1 only were more commonly 
resistant than strains with stx2 alone (p = 0.27 by Fisher 
exact test). All 23 (100%) resistant non-O157 STEC and 1 
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(12.5%) resistant O157 strain had stx1 only. Strains positive 
for eae were less likely to be resistant (n = 27; 8.4%) than 
eae-negative strains (n = 4; 23.5%); this nonsignificant dif-
ference (p = 0.07 by Fisher exact test) could be due to small 
sample sizes. All 8 resistant O157 strains and 18 (78.3%) of 
23 resistant non-O157 strains had eae, demonstrating cor-
relations between virulence genes and serogroups.
Overall, we detected a high frequency of resistance 
among non-O157 STEC (11.2%), similar to findings from 
Mexico (15%), although we evaluated fewer drugs (5). Re-
sistance to ciprofloxacin was low despite its routine use for 
treating enteric infections, perhaps because resistance de-
velopment in E. coli requires multiple mutations (9). Resis-
tance frequencies in STEC were low relative to other E. coli 
pathotypes such as extraintestinal E. coli, which may be 
attributable to differences in the source of the infections (3). 
The higher O157 resistance frequencies in Michigan 
than nationwide indicate that selection pressures vary by 
location and source. Although we observed no difference 
in resistance frequencies for counties with high versus low 
antimicrobial drug prescription rates (8), we have not in-
vestigated selection pressures from drug use in farm envi-
ronments that may affect resistance emergence in Michi-
gan. Approximately 12 × 106 kg of antimicrobial drugs are 
administered to food animals annually in the United States; 
roughly 61% of these are medically relevant. Higher resis-
tance frequencies in winter/spring (12.2%) than summer/
fall (7.5%) could be attributed to variation in prescription 
rates by season (10).
Because Michigan is not part of the Centers for Disease 
Control and Prevention Foodborne Diseases Active Surveil-
lance Network and resistance in STEC has not been widely 
researched, data about the prevalence and impact of resis-
tance are lacking. This study detected a high frequency of 
STEC resistance to antimicrobial drugs commonly used in 
human and veterinary medicine, particularly for non-O157 
serotypes, which have increased in frequency (2). Monitor-
ing resistance in STEC is essential because of the risk of 
transmitting resistant strains from food animals to humans 
and the high likelihood of horizontal transfer of resistance 
genes from STEC to other pathogens. Routine monitoring 
can uncover new treatment approaches and guide develop-
ment of strategies for controlling emergence and spread of 
resistance in STEC and other E. coli pathotypes.
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White-nose syndrome, first diagnosed in North America in 
2006, causes mass deaths among bats in North America. 
We found the causative fungus, Pseudogymnoascus de-
structans, in a 1918 sample collected in Europe, where bats 
have now adapted to the fungus. These results are consis-
tent with a Eurasian origin of the pathogen.
We report the earliest known historical incidence of the fungus Pseudogymnoascus (formerly Geo-
myces) destructans, detected in a museum specimen of a 
bat (Myotis bechsteinii) collected in France in 1918. This 
fungal pathogen causes white-nose syndrome (WNS) in 
bats (1). Since its introduction into eastern North America 
around 2006, WNS has devastated bat populations across 
the continent (2). P. destructans has also been found across 
the Eurasian landmass (3,4) without documented mass bat 
deaths. Epidemiologic evidence among bats and fungal 
genetics indicate that the fungus has been recently intro-
duced into North American bat populations (5–7).
To clarify the epidemiologic history of WNS and to 
investigate physical evidence of its presence in specific lo-
cations in the past, we screened 138 19th- and 20th-century 
bat specimens (housed at the National Museum of Natural 
History [USNM], Washington, DC) from North America (n 
= 41), Europe (n = 83), and East Asia (n = 14) for P. destruc-
tans DNA (online Technical Appendix, https://wwwnc.cdc.
gov/EID/article/23/9/17-0875-Techapp1.pdf). We sampled 
dry museum skins and intact bodies stored in 70% ethanol; 
some were originally fixed in formalin. We swabbed bat 
rostra and wings to collect potentially preserved P. destruc-
tans biomolecules and stored swabs in 100% ethanol until 
DNA extraction.
We extracted DNA in a dedicated ancient DNA labora-
tory at the National Zoological Park (Washington, DC) by 
using stringent protocols to prevent false positive results 
from modern DNA contamination (8). Before extraction, we 
removed swabs from the ethanol and let them air dry. We 
then let swabs digest overnight at 55°C in 600 μL extraction 
buffer (1× Tris-EDTA buffer, pH 8.0, 0.019 mmol/L EDTA, 
0.01 mmol/L NaCl, 1% SDS, 10 mg/mL DTT, and 1 mg/
mL proteinase K) (8). Later extractions omitted DTT. We ex-
tracted digested samples twice in 600 μL phenol and once 
in 600 μL chloroform. We removed and concentrated the 
aqueous phase by using Amicon Ultra-4 30 kDA molecular 
weight cutoff columns (Millipore Sigma, Merck, Billerica, 
MA, USA) to a final volume of ≈250 μL. We included 1 
extraction blank for every 10–11 historical samples. 
We screened extracts for P. destructans by using a pre-
viously described species-specific quantitative PCR target-
ing 103 bp (including primers) of the intergenic spacer re-
gion (9). Each extract was amplified in 2–8 replicate PCRs. 
Multiple, no-template controls (2,3) were included in each 
PCR setup. Positive products from experiments in which 
quantifiable contamination (>0.1 genome equivalents/μL 
sample) was observed in >1 negative control were discard-
ed; these experiments were repeated with fresh reagents.
One sample (USNM 231170) tested positive in 2 of 3 
PCRs. We performed a second independent extraction on this 
sample. The replicate extraction tested positive in 4 of 5 PCRs. 
Two of the USNM 231170–positive PCR products were con-
firmed by using Sanger sequencing and comparison to pub-
licly available P. destructans sequences in GenBank. These 
sequences were 100% identical to P. destructans sequences 
from North America (GenBank accession nos. JX270192.1 
